|
SKP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.51190000519108E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.85649999817628E-08 |
| Normal-vs-Stage2 |
7.563500E-03 |
| Normal-vs-Stage3 |
7.48740000000581E-08 |
| Normal-vs-Stage4 |
4.04849997970302E-09 |
| Stage1-vs-Stage2 |
3.957000E-01 |
| Stage1-vs-Stage3 |
5.451600E-01 |
| Stage1-vs-Stage4 |
1.282610E-01 |
| Stage2-vs-Stage3 |
2.687200E-01 |
| Stage2-vs-Stage4 |
8.484300E-02 |
| Stage3-vs-Stage4 |
3.409200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.39310000202286E-08 |
| Normal-vs-AfricanAmerican |
1.662180E-02 |
| Normal-vs-Asian |
3.60349999994902E-06 |
| Caucasian-vs-AfricanAmerican |
2.114600E-01 |
| Caucasian-vs-Asian |
8.551200E-01 |
| AfricanAmerican-vs-Asian |
3.070800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.64640000416472E-08 |
| Normal-vs-Female |
2.55169999574534E-08 |
| Male-vs-Female |
4.549600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.74909999711903E-08 |
| Normal-vs-Age(41-60Yrs) |
2.63950000001234E-06 |
| Normal-vs-Age(61-80Yrs) |
6.63570000059011E-08 |
| Normal-vs-Age(81-100Yrs) |
6.881900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.494800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.069200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.343400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.607000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.736400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.902200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.039300E-03 |
| Classical-VS-Follicular |
6.335800E-03 |
| Classical-VS-Other |
2.545000E-01 |
| Classical-VS-Normal |
1.32409999997751E-06 |
| Tall-VS-Follicular |
8.085000E-01 |
| Tall-VS-Other |
9.431800E-01 |
| Tall-VS-Normal |
3.31839999923034E-08 |
| Follicular-VS-Other |
8.622600E-01 |
| Follicular-VS-Normal |
5.64720004092578E-09 |
| Other-VS-Normal |
2.364600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.26260000127476E-08 |
| Normal-vs-N1 |
4.83549977836617E-10 |
| N0-vs-N1 |
3.716400E-02 |
|
|
